Titan Pharmaceuticals (TTNP) Revenue & Revenue Breakdown

OverviewOwnership Financials Chart

Titan Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$184.00K

Main Segment (Y)

Grant revenue

Main Geography (Y)

Grant revenue

Titan Pharmaceuticals Revenue by Period

Titan Pharmaceuticals Revenue by Year

Date	Revenue	Change
2023-12-31	$184.00K	206.67%
2022-12-31	$60.00K	-96.07%
2021-12-31	$1.53M	-68.46%
2020-12-31	$4.84M	33.98%
2019-12-31	$3.61M	-38.91%
2018-12-31	$5.91M	2649.30%
2017-12-31	$215.00K	-98.57%
2016-12-31	$15.06M	801.56%
2015-12-31	$1.67M	-54.17%
2014-12-31	$3.65M	-65.21%
2013-12-31	$10.48M	47.27%
2012-12-31	$7.12M	74.95%
2011-12-31	$4.07M	-59.69%
2010-12-31	$10.09M	12675.95%
2009-12-31	$79.00K	12.86%
2008-12-31	$70.00K	191.67%
2007-12-31	$24.00K	-25.00%
2006-12-31	$32.00K	-64.04%
2005-12-31	$89.00K	187.10%
2004-12-31	$31.00K	-65.17%
2003-12-31	$89.00K	-96.92%
2002-12-31	$2.89M	-36.75%
2001-12-31	$4.57M	143.19%
2000-12-31	$1.88M	526.67%
1999-12-31	$300.00K	200.00%
1998-12-31	$100.00K	-99.43%
1997-12-31	$17.50M	5733.33%
1996-12-31	$300.00K	200.00%
1995-12-31	$100.00K	-

Titan Pharmaceuticals generated $184.00K in revenue during NA 2023, up 206.67% compared to the previous quarter, and up 3.11% compared to the same period a year ago.

Titan Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2024-06-30	-	100.00%
2024-03-31	-	-100.00%
2023-12-31	$81.00K	1925.00%
2023-09-30	$4.00K	300.00%
2023-06-30	$1.00K	-98.98%
2023-03-31	$98.00K	92.16%
2022-12-31	$51.00K	1175.00%
2022-09-30	$4.00K	-97.33%
2022-06-30	$150.00K	-21.88%
2022-03-31	$192.00K	42.22%
2021-12-31	$135.00K	-48.86%
2021-09-30	$264.00K	-40.67%
2021-06-30	$445.00K	-34.75%
2021-03-31	$682.00K	-35.48%
2020-12-31	$1.06M	-5.63%
2020-09-30	$1.12M	-15.47%
2020-06-30	$1.32M	-0.82%
2020-03-31	$1.34M	9.78%
2019-12-31	$1.22M	28.51%
2019-09-30	$947.00K	88.65%
2019-06-30	$502.00K	-46.88%
2019-03-31	$945.00K	78.30%
2018-12-31	$530.00K	-67.88%
2018-09-30	$1.65M	-38.16%
2018-06-30	$2.67M	150.75%
2018-03-31	$1.06M	1734.48%
2017-12-31	$58.00K	45.00%
2017-09-30	$40.00K	-48.05%
2017-06-30	$77.00K	92.50%
2017-03-31	$40.00K	14.29%
2016-12-31	$35.00K	34.62%
2016-09-30	$26.00K	-99.83%
2016-06-30	$15.00M	100.00%
2016-03-31	-	100.00%
2015-12-31	-	100.00%
2015-09-30	-	-100.00%
2015-06-30	$760.00K	-16.58%
2015-03-31	$911.00K	-0.11%
2014-12-31	$912.00K	0.11%
2014-09-30	$911.00K	-
2014-06-30	$911.00K	-
2014-03-31	$911.00K	-
2013-12-31	$911.00K	-58.55%
2013-09-30	$2.20M	-
2013-06-30	$2.20M	-57.52%
2013-03-31	$5.17M	58.76%
2012-12-31	$3.26M	165.39%
2012-09-30	$1.23M	-9.71%
2012-06-30	$1.36M	7.09%
2012-03-31	$1.27M	-10.12%
2011-12-31	$1.41M	39.62%
2011-09-30	$1.01M	45.61%
2011-06-30	$695.00K	-26.69%
2011-03-31	$948.00K	-65.22%
2010-12-31	$2.73M	-24.28%
2010-09-30	$3.60M	168.26%
2010-06-30	$1.34M	-44.66%
2010-03-31	$2.42M	8881.48%
2009-12-31	$27.00K	100.00%
2009-09-30	-	-100.00%
2009-06-30	$29.00K	26.09%
2009-03-31	$23.00K	100.00%
2008-12-31	-	100.00%
2008-09-30	-	-100.00%
2008-06-30	$12.00K	-80.33%
2008-03-31	$61.00K	408.33%
2007-12-31	$12.00K	-

Titan Pharmaceuticals generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Titan Pharmaceuticals Revenue Breakdown

Titan Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 21	Dec 20	Dec 19
Grant revenue	$1.28M	-	-
License revenue	$13.00K	-	-
Product revenue	$236.00K	-	-
License And Service	-	$11.00K	$315.00K
Manufactured Product Other	-	$528.00K	$1.01M
Grant	-	$4.30M	$2.29M

Titan Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 21: Grant revenue (83.68%), Product revenue (15.47%), and License revenue (0.85%).

Quarterly Revenue by Product

Product/Service	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Product revenue	-	-	-	$36.00K	-	-	-	-	-	-	-	-	-
Grant revenue	$147.00K	$189.00K	$131.00K	$224.00K	-	-	-	-	-	-	-	-	-
License revenue	$3.00K	$3.00K	$4.00K	$4.00K	-	-	-	-	-	-	-	-	-
Manufactured Product Other	-	-	-	-	$89.00K	$111.00K	$101.00K	$102.00K	$115.00K	$210.00K	$195.00K	$190.00K	$304.00K
License And Service	-	-	-	-	$3.00K	$2.00K	$5.00K	-	$6.00K	-	$2.00K	-	-
Grant	-	-	-	-	$353.00K	$569.00K	$951.00K	$1.02M	$1.20M	$1.13M	$1.02M	$757.00K	$198.00K

Titan Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 22: Grant revenue (98.00%), and License revenue (2.00%).

Titan Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 21	Dec 20	Dec 19
License revenue	$13.00K	-	-
Product revenue	$236.00K	-	-
Grant revenue	$1.28M	-	-
Manufactured Product Other	-	$528.00K	$1.01M
Grant	-	$4.30M	$2.29M
License And Service	-	$11.00K	$315.00K

Titan Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 21: Grant revenue (83.68%), Product revenue (15.47%), and License revenue (0.85%).

Quarterly Revenue by Country

Country	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Grant revenue	$147.00K	$189.00K	$131.00K	$224.00K	-	-	-	-	-	-	-	-	-
License revenue	$3.00K	$3.00K	$4.00K	$4.00K	-	-	-	-	-	-	-	-	-
Product revenue	-	-	-	$36.00K	-	-	-	-	-	-	-	-	-
Manufactured Product Other	-	-	-	-	$89.00K	$111.00K	$101.00K	$102.00K	$115.00K	$210.00K	$195.00K	$190.00K	$304.00K
Grant	-	-	-	-	$353.00K	$569.00K	$951.00K	$1.02M	$1.20M	$1.13M	$1.02M	$757.00K	$198.00K
License And Service	-	-	-	-	$3.00K	$2.00K	$5.00K	-	$6.00K	-	$2.00K	-	-

Titan Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Jun 22: Grant revenue (98.00%), and License revenue (2.00%).

Titan Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
FHTX	Foghorn Therapeutics	$34.16M	$7.81M
FRTX	Fresh Tracks Therapeutics	$8.01M	-
SNTI	Senti Biosciences	$2.56M	-
SABS	SAB Biotherapeutics	$2.24M	$263.14K
VCNX	Vaccinex	$570.00K	$52.00K
TTNP	Titan Pharmaceuticals	$184.00K	-
NRBO	NeuroBo Pharmaceuticals	$7.00K	-
LIXT	Lixte Biotechnology	-	-
FWBI	Entero Therapeutics	-	-
PCSA	Processa Pharmaceuticals	-	-
CVKD	Cadrenal Therapeutics	-	-
GOVX	GeoVax Labs	-	$300.68K
THRD	Third Harmonic Bio	-	-
INDP	Indaptus Therapeutics	-	-
QNRX	Quoin Pharmaceuticals	-	-
SLRX	Salarius Pharmaceuticals	-	-
KTTA	Pasithea Therapeutics	-	-

TTNP Revenue FAQ

What is Titan Pharmaceuticals’s yearly revenue?

Titan Pharmaceuticals's yearly revenue for 2023 was $184K, representing an increase of 206.67% compared to 2022. The company's yearly revenue for 2022 was $60K, representing a decrease of -96.07% compared to 2021. TTNP's yearly revenue for 2021 was $1.53M, representing a decrease of -68.46% compared to 2020.

What is Titan Pharmaceuticals’s quarterly revenue?

Titan Pharmaceuticals's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). TTNP's quarterly revenue for Q4 2023 was $81K, a 1925.00% increase from the previous quarter (Q3 2023), and a 58.82% increase year-over-year (Q4 2022).

What is Titan Pharmaceuticals’s revenue growth rate?

Titan Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -87.94%, and for the last 5 years (2019-2023) was -94.90%.

What are Titan Pharmaceuticals’s revenue streams?

Titan Pharmaceuticals's revenue streams in c 21 are Grant revenue, License revenue, and Product revenue. Grant revenue generated $1.28M in revenue, accounting 83.68% of the company's total revenue License revenue generated $13K in revenue, accounting 0.85% of the company's total revenue Product revenue generated $236K in revenue, accounting 15.47% of the company's total revenue

What is Titan Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 21, the largest source of revenue of Titan Pharmaceuticals was Grant revenue. This segment made a revenue of $1.28M, representing 83.68% of the company's total revenue.